X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA FRESENIUS KABI ONCO. TORRENT PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 28.1 22.1 127.2% View Chart
P/BV x 5.4 3.1 171.8% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 TORRENT PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
FRESENIUS KABI ONCO.
Mar-13
TORRENT PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,768176 1,004.4%   
Low Rs1,18679 1,510.3%   
Sales per share (Unadj.) Rs346.137.7 918.4%  
Earnings per share (Unadj.) Rs55.25.1 1,083.2%  
Cash flow per share (Unadj.) Rs73.36.7 1,090.4%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.142.5 604.2%  
Shares outstanding (eoy) m169.22158.23 106.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.33.4 126.4%   
Avg P/E ratio x26.825.0 107.1%  
P/CF ratio (eoy) x20.118.9 106.4%  
Price / Book Value ratio x5.73.0 192.1%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,88720,135 1,241.1%   
No. of employees `00011.81.2 1,022.7%   
Total wages/salary Rs m9,934703 1,412.7%   
Avg. sales/employee Rs Th4,971.55,176.2 96.0%   
Avg. wages/employee Rs Th843.2610.4 138.1%   
Avg. net profit/employee Rs Th792.4699.6 113.3%   
INCOME DATA
Net Sales Rs m58,5695,963 982.2%  
Other income Rs m2,23318 12,405.6%   
Total revenues Rs m60,8025,981 1,016.6%   
Gross profit Rs m13,7731,430 963.1%  
Depreciation Rs m3,069258 1,190.1%   
Interest Rs m2,056-26 -7,906.2%   
Profit before tax Rs m10,8811,216 894.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,545342 451.5%   
Profit after tax Rs m9,336806 1,158.4%  
Gross profit margin %23.524.0 98.1%  
Effective tax rate %14.228.1 50.5%   
Net profit margin %15.913.5 117.9%  
BALANCE SHEET DATA
Current assets Rs m53,8415,102 1,055.4%   
Current liabilities Rs m31,6122,385 1,325.2%   
Net working cap to sales %38.045.6 83.3%  
Current ratio x1.72.1 79.6%  
Inventory Days Days97150 64.8%  
Debtors Days Days84113 73.9%  
Net fixed assets Rs m42,0795,148 817.4%   
Share capital Rs m846158 534.9%   
"Free" reserves Rs m42,6556,556 650.7%   
Net worth Rs m43,5016,732 646.2%   
Long term debt Rs m22,408952 2,353.3%   
Total assets Rs m101,25010,388 974.7%  
Interest coverage x6.3-45.8 -13.7%   
Debt to equity ratio x0.50.1 364.2%  
Sales to assets ratio x0.60.6 100.8%   
Return on assets %11.37.5 149.9%  
Return on equity %21.512.0 179.3%  
Return on capital %19.614.6 134.4%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m20,0665,298 378.8%   
Fx outflow Rs m5,3041,772 299.3%   
Net fx Rs m14,7623,525 418.7%   
CASH FLOW
From Operations Rs m10,1271,274 794.8%  
From Investments Rs m-7,869-1,204 653.5%  
From Financial Activity Rs m-1,918-196 978.1%  
Net Cashflow Rs m212-126 -167.5%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 7.0 0.3 2,340.0%  
FIIs % 12.6 9.6 131.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 9.1 96.7%  
Shareholders   26,511 42,599 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - UNICHEM LAB COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS